Evaluating the Immuno-Oncology Potential of Compounds Using Human In Vitro TME Models
Dr. Alison O’Mahony, Eurofins DiscoverX discusses the use of in vitro models of the human tumor microenvironment (TME) to qualify immuno-oncology candidates, prioritize combination strategies and predict clinical outcomes. She gives an overview on the recent failures of IDO inhibitors in the clinic and the immuno-oncology potential of anti-PD-1 antibodies including pembrolizumab.
Publish Date:
June 18, 2018
Views: 0
Related Multimedia
-
Humanized Mouse Models for Hematopoietic Stem Cell Research: Principles and Pitfalls
Publish Date: March 09, 2018 -
Qualification of Ancillary/Raw Materials for Clinical Use
Publish Date: June 20, 2018
Explore Our Products
-
Diseased Human Peripheral Blood Products, Melanoma
Primary human cells, fresh or frozen -
Diseased Human Peripheral Blood Products, Acute Lymphoblastic Leukemia (ALL)
Primary human cells, frozen -
Diseased Human Peripheral Blood Products, Head and Neck Cancer
Primary human cells, fresh or frozen -
Diseased Human Peripheral Blood Products, Bladder Cancer
Primary human cells, fresh or frozen
